幽门螺杆菌的治疗现状  

Current Status of Treatment of Helicobacter Pylori

作　　者：刘敏芝[1] 李运泽[1] LIU Min-zhi;LI Yun-ze(Department of Gastroenterology,Liuzhou People's Hospital,Liuzhou 545006,Guangxi,China)

机构地区：[1]柳州市人民医院消化内科,广西柳州545006

出　　处：《医学信息》2021年第15期35-38,共4页Journal of Medical Information

基　　金：广西自治区卫生厅自筹经费科研项目(编号:Z20170673)。

摘　　要：幽门螺杆菌(Hp)与胃癌及癌前病变的发生密切相关,国际癌症研究机构和世界卫生组织已经将Hp划分为Ⅰ类致癌物,Hp根除治疗利大于弊,目前根除Hp感染已成为全球关注的热点。Hp感染率逐渐升高,再感染机率也逐年上升,随着抗生素耐药发生率的不断升高,首次根除Hp治疗的成功率仍较低。国内外有大量研究探索更有效的根除Hp的新方案,如高剂量二联疗法、Hp的靶向治疗、Hp疫苗的研发等。本文主要就近年来根除Hp的相关研究进行综述,以期为临床治疗Hp感染提供参考。Helicobacter pylori(Hp)is closely related to the occurrence of gastric cancer and precancerous lesions.The International Agency for Research on Cancer and the World Health Organization have classified Hp as a Class I carcinogen.The benefits of Hp eradication treatment outweigh the disadvantages.At present,eradication of Hp infection has become a global concern.Hot spot.The Hp infection rate is gradually increasing,and the re-infection rate is also increasing year by year.With the increasing incidence of antibiotic resistance,the success rate of the first eradication of Hp treatment is still low.There are a large number of studies at home and abroad to explore more effective new solutions to eradicate Hp,such as high-dose dual therapy,Hp targeted therapy,and the development of Hp vaccines.This article mainly reviews the related research on Hp eradication in recent years,hoping to provide reference for clinical treatment of Hp infection.

关 键 词：幽门螺杆菌 Ⅰ类致癌物 铋剂 Hp尿素酶 

分 类 号：R378.2[医药卫生—病原生物学]